News
AVEO
--
0.00%
--
Press Release: AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
Dow Jones · 4d ago
AVEO Oncologyto Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021...
BusinessWire - BZX · 4d ago
10 “Strong Buy” Healthcare Stocks With Over 100% Upside Potential According to Top Analysts
TipRanks.com · 04/27 13:58
Earnings Preview: AVEO Pharmaceuticals (AVEO) Q1 Earnings Expected to Decline
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 04/22 17:33
Hepatocyte Growth Factor Market Size Poised to Touch 59 Million USD by 2025
Apr 22, 2021 (Market Insight Reports) -- Selbyville, Delaware. The latest report on Hepatocyte Growth Factor market envelops all critical aspects of this...
Market Insight Reports · 04/22 06:26
Global Fibroblast Growth Factor Receptor 3 Market Insights, Overview, Analysis and Forecast 2021-2026
Apr 20, 2021 (Heraldkeepers) -- The Fibroblast Growth Factor Receptor 3 market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 04/20 08:25
Global Receptor Tyrosine Protein Kinase ERBB 3 Market Analysis 2016-2020 and Forecast 2021-2026
Apr 17, 2021 (Heraldkeepers) -- Product Type Coverage (Market Size & Forecast, Major Company of Product Type...
Heraldkeepers · 04/17 08:02
8-K: AVEO PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- NASDAQ false 0001325879 0001325879 2021-04-15 2021-04-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/17 04:21
BRIEF-Aveo Appoints Kevin Cullen, M.D., To Its Board Of Directors
reuters.com · 04/16 11:15
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in ...
Business Wire · 04/16 11:00
Kidney Cancer Drugs Market Research Report in Global Market by Insights, Size, Share, Trend and Forecast 2020 - 2027 By Ameco Research
pune, India, Fri, 16 Apr 2021 04:53:36 / Comserve Inc. / -- A fresh report titled "Kidney Cancer Drugs Market" has been presented by Ameco Research. It...
Comserve · 04/16 08:55
AVEO Pharma US Patent & Trademark Office Abstract For Co.'s 'ANTI-GDF-15 ANTIBODIES'
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210101968%22.PGNR.&OS=DN/20210101968&RS=DN/2021
Benzinga · 04/08 14:57
Fibroblast Growth Factor Receptor 3 Market Size, Industry Share 2021 ,Market Research with Growth, Manufacturers, Segments and 2027 Forecasts Research
Apr 07, 2021 (Market Insight Reports) -- The latest report as Fibroblast Growth Factor Receptor 3 Market acknowledges Size, Application Segment, Type,...
Market Insight Reports · 04/07 18:12
Bursitis Treatment Market Overview, New Opportunities & SWOT Analysis by 2025 | Pfizer, Amgen, Bayer, MediaPharma
Market Insight Reports · 04/06 14:29
Global Hepatocyte Growth Factor Market 2020 Industry Analysis, Size, Share, Growth, Trend and Forecast to 2026
Apr 05, 2021 (CDN Newswire via Comtex) -- The recently uploaded report titled Global Hepatocyte Growth Factor Market Growth 2020-2025 delivers detailed...
CDN Newswire · 04/05 22:02
C-MET & HGF Inhibitors Market Size Is Projected To Surpass US$ 6700.1 Mn By 2026
Apr 05, 2021 (Market Insight Reports) -- The global C-MET & HGF Inhibitors market size is projected to reach US$ 6700.1 million by 2026, from US$ 1848.5...
Market Insight Reports · 04/05 11:14
Nasopharyngeal Cancer Drug Market Size, Share, Growth, Industry Analysis, Global Competitive Analysis, 2021 Worldwide Trends, Business Opportunities and Demand Forecast to 2027
Apr 05, 2021 (The Expresswire) -- Global "Nasopharyngeal Cancer Drug Market" 2021 Industry Research Report is profound investigation by authentic and ebb and...
The Express Wire · 04/05 08:29
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
A slew of drugs, including four new molecular entities, were approved in the month of March. NMEs are drugs that contain active moieties that have never been approved by the Food and Drug Administration previously and are indicators of innovation in drug r...
Benzinga · 04/02 12:01
Knee Bursitis Treatment Market Analysis By Business Share, Development Trends, Segmentation, Opportunities and Forecast to 2025
Apr 01, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global "Knee Bursitis Treatment Market"...
The Express Wire · 04/01 06:47
Global C-MET & HGF Inhibitors Market 2020 Growth Drivers, Regional Outlook, Competitive Strategies and Forecast up to 2025
Mar 29, 2021 (CDN Newswire via Comtex) -- The recently uploaded report titled Global C-MET & HGF Inhibitors Market Growth 2020-2025 delivers detailed...
CDN Newswire · 03/29 17:55
Webull provides a variety of real-time AVEO stock news. You can receive the latest news about Aveo through multiple platforms. This information may help you make smarter investment decisions.
About AVEO
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).